Clinical Trial Data on Shenfu Injection for Sepsis-Induced Cardiomyopathy

A dataset from a randomized controlled trial evaluating the early administration of Shenfu Injection for preventing sepsis-induced cardiomyopathy. The trial analyzed 152 patients in an ICU setting, with primary outcomes measured over 7 days. The data was published by Yaohui Liu on figshare in March 2026.

Use Cases

• Analyze the incidence of sepsis-induced cardiomyopathy based on patient group assignment and treatment protocols.
• Model the effect of Shenfu Injection on biomarker levels like NT-proBNP using the described generalized linear mixed model.
• Compare hemodynamic parameters and organ function outcomes between treatment and control groups.
• Assess correlations between baseline characteristics (gender, age, septic shock) and clinical outcomes such as 28-day mortality.

Strengths

• Data originates from a randomized controlled trial, a robust study design for causal inference.
• Includes results for 152 patients with detailed outcome measures over a 7-day period.
• Published under a CC-BY-4.0 license, permitting open reuse and redistribution.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 48.4 KB, indicating limited scope.

Provenance

Source

Yaohui Liu via figshare.

Collection Method

Data collected from a randomized controlled trial in an ICU setting.

Time Range

The trial period is not specified, but data was published in 2026.

Freshness

Last updated 2026-03-18 07:39:54; freshness should be verified.

Geography

Likely China, based on the clinical trial registration identifier.